secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018477
Event type: earnings
Sentiment:  neutral
Materiality: 0.35
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q1 2023 net loss $27.7M; cash runway unchanged into Q4 2024
--------------------------------------------------------------------------------

- Net loss $27.7M ($0.58 loss per share) vs $29.5M ($0.63) in Q1 2022.
- Cash, cash equivalents & marketable securities $172.3M; funding operations into Q4 2024.
- R&D expenses decreased to $21.8M from $22.8M YoY.
- PRT2527 CDK9 inhibitor solid tumor dose escalation complete; RP2D in hematological malignancies expected 2H 2023.
- Phase 1 dose escalation of PRT3789 (SMARCA2 degrader) ongoing; oral candidate nomination expected early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/0000950170-23-018477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/prld-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer